Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Jianxin Yang M.D., Ph.D. | CEO, President of R&D and Executive Director | 7.48M | -- | 1964 |
| Ms. Weicong Ni | CFO & Joint Company Secretary | -- | -- | 1991 |
| Ms. Ying Hua Zhang | Senior VP & Chief Operating Officer | -- | -- | 1979 |
| Dr. Ngai Chiu Tse M.D., Ph.D. | Senior VP & Chief Scientific Officer | -- | -- | 1968 |
| Mr. Michael J. Choi M.B.A. | Chief Commercial & Strategic Officer | -- | -- | 1975 |
| Dr. Yujuan La | Senior Vice President of Product Development | -- | -- | 1978 |
| Ms. Mei Yee Yung FCIS, FCS | Joint Company Secretary | -- | -- | 1965 |
CStone Pharmaceuticals
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 164
Description
CStone Pharmaceuticals, a biopharmaceutical company, researches, develops, and commercializes immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and internationally. It offers Sugemalimab, a monoclonal antibody against programmed death (PD) ligand 1; GAVRETO, an RET inhibitor for the treatment of patients with advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers; and avapritinib, a KIT/PDGFRA inhibitor to treat adults with unresectable or metastatic gastrointestinal stromal tumors harboring a PDGFRA exon 18 mutation. The company's product pipeline includes Nofazinlimab, a PD-1 antibody for the treatment of patients with hepatocellular carcinoma; and Ivosidenib, an isocitrate dehydrogenase 1 (IDH1) inhibitor to treat adults with relapsed or refractory acute myeloid leukemia with an IDH1 mutation. Its products also comprise CS1002, CS2006, CS3005, CS2007, CS2008, CS6001, and CS500 for solid tumors; and CS5001 for solid tumors and hematologic malignancies. The company was incorporated in 2015 and is headquartered in Suzhou, China.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
Recent Events
Recent Events Information Not Available